COMPARISON OF THE EFFICACY OF PHOTOTHERMAL ACTIVATED PLATELET RICH PLASMA AND CONVENTIONAL PLATELET RICH PLASMA IN IMPROVEMENT OF MELASMA

COMPARISON OF THE EFFICACY OF PHOTOTHERMAL ACTIVATED PLATELET-RICH PLASMA AND CONVENTIONAL PLATELET-RICH PLASMA IN IMPROVEMENT OF MELASMA

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260318004

Enrollment

Registered

2026-03-18

Start date

2026-02-15

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial melasma, a chronic acquired hyperpigmentation disorder characterized by symmetric light to dark brown macules and patches on sun-exposed areas of the face. Melasma, facial hyperpigmentation, platelet rich plasma, photothermal activation, skin rejuvenation, melanogenesis, dermal remodeling, pigmentary disorders, split face study, randomized controlled trial

Interventions

Autologous platelet rich plasma is prepared from the participant own blood using a standardized centrifugation protocol. The obtained platelet rich plasma is then subjected to photothermal activation

Experimental Biological/Vaccine,Experimental Biological/Vaccine

Photothermal activated platelet rich plasma,Conventional platelet rich plasma

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients with symmetrical Epidermal and Mixed type melasma. 2.Fitzpatrick skin types III-V.

Exclusion criteria

Exclusion criteria: 1.Patient using oral contraceptives, hormone replacement therapy. 2.Pregnant or lactating women 3.Disorder of Hematopoiesis (platelet dysfunction, thrombocytopenia, bleeding tendencies) 4.Patient on other treatments of melasma (chemical peeling, skin whitening agents, topical retinoids, topical hydroquinone within 3 months and laser treatment within 6 months) 5.Patient with active systemic disease 6.Local skin infection or inflammation in the areas to be treated with PRP. 7.Patient on consistent use of oral tranexamic acid.

Design outcomes

Primary

Measure	Time frame
modified Melasma Area and Severity Index Baseline, 4 weeks, 8 weeks, and 12 weeks Modified Melasma Area and Severity Index assessed by two blinded dermatologists from standardized facial photography	—

Secondary

Measure	Time frame
Melanin index Baseline, 4 weeks, 8 weeks, and 12 weeks Assessed by Mexameter,Erythema index Baseline, 4 weeks, 8 weeks, and 12 weeks Assessed by Mexameter,Patient satisfaction score 4 weeks, 8 weeks, and 12 weeks Visual analog scale,Patient improvement score 12 weeks Participant assessed 4 point improvement scale,Adverse events After each treatment session and at follow up visits at 12 weeks Clinical assessment of treatment related adverse events including pain, erythema, edema, bruising, eczema, and skin irritation,Dermoscopic pigmentation pattern Baseline and 12 weeks Descriptive dermoscopic documentation of pigmentation distribution for qualitative comparison	—

Measure

Time frame

Melanin index Baseline, 4 weeks, 8 weeks, and 12 weeks Assessed by Mexameter,Erythema index Baseline, 4 weeks, 8 weeks, and 12 weeks Assessed by Mexameter,Patient satisfaction score 4 weeks, 8 weeks, and 12 weeks Visual analog scale,Patient improvement score 12 weeks Participant assessed 4 point improvement scale,Adverse events After each treatment session and at follow up visits at 12 weeks Clinical assessment of treatment related adverse events including pain, erythema, edema, bruising, eczema, and skin irritation,Dermoscopic pigmentation pattern Baseline and 12 weeks Descriptive dermoscopic documentation of pigmentation distribution for qualitative comparison

—

Countries

Thailand

Contacts

Public ContactNattachar Ranoppawan

Chulabhorn International College of Medicine, Thammasat University

nattachar.ran@dome.tu.ac.th026564500

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: May 1, 2026